DE-LYCRA/DCC
9.5.2024 03:01:32 CEST | Business Wire | Press release
The LYCRA Company, a global leader in developing innovative, sustainable solutions for the apparel and personal care industries, announced today that it has signed a letter of intent with Dairen Chemical Corporation (DCC) to convert QIRA®—the next generation of 1,4 butanediol (BDO)—into low-impact PTMEG, the main ingredient in patented bio-derived LYCRA® fiber. Dairen will be the first company in the world to mass produce this low-impact bio-PTMEG at scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240509462079/en/
Left to Right: Steve Stewart, chief brand and innovation officer, The LYCRA Company, and Shean-Tung Lin, Chairman, Dairen Chemical Corporation (DCC), sign a letter of intent for DCC to convert QIRA® into low-impact PTMEG for bio-derived LYCRA® fiber. (Photo: Business Wire)
In September 2022, The LYCRA Company and Qore® announced they were joining forces to enable the production of bio-derived LYCRA® fiber made with QIRA®. Now, DCC joins this distinctive collaboration, converting QIRA® into bio-PTMEG. This unique PTMEG will make up the renewable portion of LYCRA® fiber, accounting for 70% of the fiber’s content. It is being made exclusively for The LYCRA Company to its stringent specifications. With its low-impact allyl alcohol process, DCC has pioneered a technology that creates the lowest-impact PTMEG available, which is cleaner and has a lower carbon footprint than product produced with natural gas or coal.1
The LYCRA Company, Qore®, and DCC are united by a shared commitment to R&D, health and safety, sustainability, and conservation. To mark this event, Steve Stewart, The LYCRA Company’s chief brand and innovation officer, presented DCC with a Green Partner Award. The award acknowledges DCC’s ongoing sustainability efforts and commitment to creating low-impact products.
“Our collaboration heralds a brand-new era of environmentally conscious production activities, fueled by our shared commitment to reducing carbon footprints and developing world-leading eco-friendly solutions,” said DCC’s chairman, Lin Shean-Tung. “Sustainability is not merely a trend, but an imperative for the future of our planet. We are honored to receive the Green Partner Award and embark on this journey alongside The LYCRA Company, advancing sustainable practices in the industry.”
Available in early 2025, patented bio-derived LYCRA® fiber made with QIRA® will be the world’s first renewable spandex available on a large scale. By using annually renewable dent corn, an initial screening calculation indicates that the carbon footprint of LYCRA® fiber potentially could be reduced by up to 44 percent2 compared to LYCRA® fiber without bio-derived materials. Further, the fiber will offer equivalent performance to traditional LYCRA® fiber, making it an easy replacement for mills, brands and retailers.
“We are excited to collaborate with DCC to bring bio-derived LYCRA® fiber made with QIRA® to market and realize our shared vision for a more sustainable value chain,” said Stewart. “Given the combination of using bio-derived input from corn, plus conversion at a state-of-the-art QORE® facility run on wind power, and transformation to PTMEG using DCC’s low-impact process, we anticipate the potential for additional reductions as we go into production.”
For many years, Dairen has demonstrated its sustainability efforts in raw materials management, waste elimination, process enhancement, innovations, and more. It has also achieved significantly lower carbon emissions in its product offerings than its competition.
“Sustainability has evolved from fulfilling requirements to being a competitive advantage,” said Simon Chuang, vice president of global sourcing and procurement at The LYCRA Company. “We’re committed to selecting, promoting, and expanding our business with supply partners like DCC who embrace and drive meaningful sustainability efforts.”
Visit lycra.com/qira to learn more about bio-derived LYCRA® fiber made with QIRA®.
1Estimate from Cradle-to-Gate Screening PCF for a representative DAIREN PTMEG manufacturing facility, year 2023, prepared by DNV Business Assurance Co., Ltd.
2Estimate from Cradle-to-Gate Screening LCA for a representative LYCRA® fiber manufacturing facility, June 2022, prepared by Ramboll Americas Engineering Solutions, Inc.
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries and owns the leading consumer brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL®. Headquartered in Wilmington, Delaware, U.S., The LYCRA Company is recognized worldwide for its sustainable products, technical expertise, and marketing support. The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit lycra.com.
About Qore® LLC
Formed through a joint venture by Cargill and HELM AG, Qore® helps leading brands replace fossil-based chemistries with bio-derived intermediates. At the heart of the joint venture is the production of QIRA®, the next-generation bio-derived 1,4-butanediol (BDO). Made biologically through the fermentation of plant-based sugars, QIRA® can save up to 86% of greenhouse gas emissions when replacing today’s widely used chemical intermediates made from traditional fossil sources. Bio-derived QIRA® can be used the same way as its fossil counterpart but with significantly better environmental performance. Qore® and QIRA® are trademarks of Qore® LLC. For more information and inquiries visit https://www.myqira.com/.
About Dairen Chemical Corporation (DCC)
Founded in 1979, DCC is a leading maker of acetyl and allyl chemicals. The company board has been chaired by Mr. Lin Shean-Tung since June 2019. DCC operates seven production sites in Asia and serves customers in more than one hundred countries. Major products include Vinyl Acetate Monomer, Vinyl Acetate Ethylene (VAE) Emulsion, VAE Redispersible Powder, Allyl Alcohol, 1,4-Butanediol and PTMEG. Headquartered in Taipei, Taiwan, its productions sites are in Taiwan, China, Singapore and Malaysia. Under the leadership of Chairman Lin, DCC is expanding its international activities and enhancing its global presence.
LYCRA® is a trademark of The LYCRA Company.
QIRA® is a trademark of Qore®.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240509462079/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents23.4.2026 13:29:00 CEST | Press release
Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agentsA manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol’s clinical development under FDA Fast Track designationThe program demonstrates GE HealthCare’s commitment to advancing novel imaging agents to address unmet patient needs GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by t
Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform23.4.2026 13:13:00 CEST | Press release
New structure to drive AI-powered innovation and international expansion Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics. By automating patient management, scheduling, and administrative workflows, it enables healthcare professionals to focus entirely on patient care. A core element of the new strategy is a strong focus on Artificial Intelligence. Clinicore is evolving into a smart assistant, utilizing AI-driven features for automated treatment documentation, intelligent onboarding tools, and advanced process automation. This ensures that clinics can operate at maximum efficiency
NIQ Launches Commerce Lab to Build the Data and Measurement Layer for AI-Driven Commerce23.4.2026 13:00:00 CEST | Press release
NielsenIQ (NYSE: NIQ) today announced the launch of NIQ Commerce Lab, where the company is building the technology infrastructure for AI-driven commerce. The Lab will develop the data platforms, APIs, and measurement systems that power how products are discovered, evaluated, and purchased in AI-mediated environments. This includes what the industry often refers to as agentic commerce, but extends across quick commerce, social commerce, and other emerging channels—where AI is becoming the common layer shaping how consumers navigate choices and how decisions are made in real time. AI systems are rapidly moving from supporting decisions to making them—playing an increasingly central role in how commerce operates. Their effectiveness depends on the intelligence behind them. AI is Becoming the Operating Layer of Global Commerce NIQ ensures that the intelligence behind these systems is accurate, complete, and grounded in real-world behavior—reflecting how consumers actually buy, what product
Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights23.4.2026 12:10:00 CEST | Press release
Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs. 2024 - Rare sales at €906m, growing 22.3% vs. 2024 Giuseppe Accogli leaving to pursue another opportunity, Group CFO Jean-Marc Bellemin named Interim CEO while new CEO search is underway Record €885m Research & Development (R&D) investment underscores continued commitment to innovation across respiratory, rare disease and specialty care Sustainability leadership further strengthened through B Corp recertification and progress on Carbon Minimal Inhaler (CMI) innovation Chiesi Group (“Chiesi”), an international research‑focused biopharmaceutical company and certified B Corp, today announced its financial results for the year ended 31 December 2025. Chiesi reported €3.625 billion in consolidated revenues,
REPLY S.p.A.: Shareholders’ Meeting Approves the 2025 Financial Statements23.4.2026 12:05:00 CEST | Press release
Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);Group net profits of €250.9 million (€211.1 million in 2024).Approval of the proposal to distribute a dividend of €1.35 per share.Approval of the plan for the purchase and/or disposal of treasury shares. The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] held today approved the Financial Statements for the financial year 2025, confirming the distribution of a gross dividend of €1.35 per share. The dividend will be paid on 20 May 2026, with dividend date set on 18 May 2026 (record date on 19 May 2026). Approval of the 2025 financial statements The Reply Group closed the 2025 financial year with a consolidated turnover of €2,483.6 million, recording a 8.0% increase compared to €2,300.5 million in 2024. Consolidated EBITDA was €467.6 million, up 13.9% compared to €410.6 million recorded for the year 2024. EBIT, from January to December, was €397.1 million, up 18.5% compared to €330.4 million recorded for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom